2011, Protein Expression and Protein Production

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2011

Protein Expression

Protein Production

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

The Pharma Data

DECEMBER 3, 2020

Results demonstrated a substantial decrease in the time to diagnosis from >6 years of age (2011-2015) to <2 years of age (2019-2020). protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological Na V 1.1 .–( BUSINESS WIRE )– Stoke Therapeutics , Inc.

Protein Expression

Protein Expression Clinical Trials Pharmacokinetics Trials

Key considerations before commencing cell line development

Drug Target Review

JULY 5, 2023

A good introduction to the use of CHO cells for biotherapeutics production can be found in an article commemorating the 20th anniversary of the approval of a product produced using CHO cells. 2011), 108: 2141-2150 Schmieder V, Fieder J, et al. 2016), 32: 1301-1307 Matasci M, Baldo L, et al.

Engineering

Engineering DNA Laboratories Production

Drug Discovery Digest

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

Key considerations before commencing cell line development

Stay Connected